Manipal Health buys Kinder Hospital for ₹130 crore in 2026

Deal announced through exchange filing

Manipal Health Enterprises Ltd has signed an agreement to acquire the entire operations and assets of Kinder Women’s Hospital and Fertility Centre in Bengaluru for ₹130 crore. The company disclosed the transaction in an exchange filing, positioning the purchase as an expansion of its hospital network in the city. The agreement is structured as a Business Transfer Agreement (BTA) rather than a share acquisition. That means Manipal Health is buying the hospital business itself, including its operations and assets, instead of purchasing shares of the owning company. The seller is Kindorama Healthcare Private Ltd, which currently owns Kinder Women’s Hospital and Fertility Centre. The filing dates the execution of the BTA to August 17, 2026. The acquisition is to be funded entirely through cash consideration.

What Manipal Health is buying

The transaction covers the “entire business operations and assets” of Kinder Women’s Hospital and Fertility Centre. The facility is located in the Doddanekundi Industrial Area of Bengaluru. According to the disclosure, the hospital was commissioned in 2022. It currently operates with a capacity of 100 beds. By buying the business through a BTA, the acquirer takes over the operating set-up and assets tied to the hospital business, subject to the terms in the agreement. The filing also clarifies that the transaction is aligned with Manipal Health’s existing healthcare business. The company said it expects the deal to create further growth opportunities, without detailing financial targets beyond the disclosed consideration. The acquirer also stated that this is not a related-party transaction.

Consideration, structure, and payment terms

Manipal Health will pay ₹130 crore for the acquisition, and the payment will be made entirely in cash. The acquisition is not structured as a purchase of equity shares in the owning entity. Instead, the transaction transfers the hospital business, including operations and assets, to Manipal Health. This structure typically requires a set of approvals and condition fulfilments specific to business and asset transfers. In its disclosure, Manipal Health highlighted that the acquisition is subject to statutory and customary approvals, primarily those required for the change in ownership of the hospital. The company also said the deal will be completed once the conditions specified in the BTA and the necessary approvals are fulfilled. No additional payment components, earn-outs, or deferred consideration were disclosed in the provided filing details.

Expected completion timeline and approvals

Manipal Health expects the transaction to be completed within 90 days of signing the agreement. The timeline is contingent on meeting conditions precedent set out in the Business Transfer Agreement. The key gating item noted in the filing is obtaining statutory and customary approvals linked to the ownership change of the hospital. Such approvals can include sector-specific permissions and routine regulatory clearances, depending on the assets and licenses being transferred. The company did not specify a firm closing date, only the expected window. The disclosure frames the timeline as an expectation rather than a guarantee, reinforcing that completion depends on approvals. Manipal Health’s filing indicates that completion will occur after all stipulated conditions are satisfied. This keeps the transaction’s close tied directly to the approvals workflow.

Kinder Hospital’s disclosed operating metrics

Kinder Women’s Hospital and Fertility Centre reported revenue from operations of ₹20.75 crore for the financial year ended March 31, 2026, according to the exchange filing cited in the report. The hospital’s capacity is listed as 100 beds. The facility’s commissioning year was disclosed as 2022. These metrics provide a snapshot of the asset Manipal Health is acquiring through the business transfer route. The report also notes that the acquisition consideration represents a meaningful premium relative to the disclosed annual revenue figure. Based on the available numbers, the ₹130 crore consideration is about 6.3 times the FY2026 revenue from operations of ₹20.75 crore. The filing does not provide profitability, occupancy, or margin data for the facility. It also does not include any disclosed debt, liabilities, or working capital adjustments tied to the acquisition.

Key deal facts at a glance

How this fits into Manipal Health’s broader expansion

The company has been active across acquisitions and capacity additions, especially as it prepares for an initial public offering (IPO). Separately, a company executive has said Manipal Health plans to spend ₹4,000 crore to increase its bed capacity by over 18% in the next few years, ahead of the IPO launch referenced in the report. Manipal Health has also received SEBI approval for a planned $1.1 billion IPO, according to a regulatory notification mentioned in the provided text. In prior years, the group expanded through multiple deals, including acquiring the Sahyadri Hospitals chain for around ₹6,400 crore. It also picked up controlling stakes in AMRI Hospitals for around ₹2,300 crore in 2023 and Medica Synergie for up to ₹1,400 crore in 2024, as stated in the provided material. These transactions indicate a consistent inorganic growth strategy alongside capacity additions.

Recent real estate and asset moves mentioned alongside the deal

In Bengaluru, the group has also taken a long-term lease of a multi-speciality hospital building in Yelahanka through a lease tenure of 29 years and 11 months, with total rental outgo estimated at around ₹816.12 crore over the lease period after factoring in scheduled escalations. The starting monthly rent cited is ₹1.27 crore, and the security deposit is ₹7.64 crore. The lease includes a 10% rent escalation in the sixth year, followed by 15% increases every three years thereafter for the remainder of the term. In Mumbai, the company completed an acquisition of hospital property and development rights in Andheri for ₹495 crore, with the transaction registered on May 6, 2026, and stamp duty of ₹29.22 crore. The provided text also notes that this second leg took the total deal value to around ₹908 crore, including an earlier ₹413 crore transaction registered in 2024.

Market impact and what to track next

For investors tracking the healthcare space, the Kinder Hospital acquisition adds a defined asset in Bengaluru with disclosed capacity of 100 beds and FY2026 revenue from operations of ₹20.75 crore. The deal’s cash consideration of ₹130 crore is a clear, quantifiable capital allocation decision alongside other expansion moves cited in the broader context. The company has stated the transaction is not a related-party deal, and that neither promoters nor group companies hold an interest in the seller. The filing also references that Manipal Health notified the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The key near-term variable is execution: completion within 90 days depends on statutory and customary approvals related to change of ownership. Investors will likely monitor the company’s subsequent disclosures on fulfilment of conditions precedent and closing updates.

Conclusion

Manipal Health Enterprises’ ₹130 crore cash acquisition of Kinder Women’s Hospital and Fertility Centre, executed through a Business Transfer Agreement on August 17, 2026, adds a commissioned-in-2022, 100-bed facility in Bengaluru. The deal is expected to close within 90 days, subject to statutory and customary approvals required for the ownership change. The next confirmed step is completion after the BTA conditions precedent and approvals are fulfilled, with any closing update expected through follow-on exchange communication.